# Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213

> **NCT05305989** · PHASE2 · COMPLETED · sponsor: **Kadmon, a Sanofi Company** · enrollment: 23 (actual)

## Conditions studied

- Chronic Graft-versus-host-disease

## Interventions

- **DRUG:** Belumosudil 200 mg QD
- **DRUG:** Belumosudil 200 mg BID
- **DRUG:** Belumosudil 400 mg QD

## Key facts

- **NCT ID:** NCT05305989
- **Lead sponsor:** Kadmon, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-23
- **Primary completion:** 2024-06-06
- **Final completion:** 2024-06-06
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05305989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05305989, "Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05305989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*